Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06853912 · ClinicalTrials.gov registry record · Phase 2

Psilocybin With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring PTSD & Alcohol Use Disorder (AUD)

A Phase 2 study of PTSD and Alcohol Use Disorder (AUD), sponsored by Nathan Brashares Sackett.

Recruiting
Registry status
Phase 2
Development phase
40
Enrollment target
1
Study location

NCT06853912 is a Phase 2 study of PTSD and Alcohol Use Disorder (AUD) that is actively recruiting participants, run by Nathan Brashares Sackett. The registered enrollment target is 40 participants, below the 302-participant average among 154 other PTSD trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06853912, a Phase 2 study of PTSD and Alcohol Use Disorder (AUD), is actively recruiting participants, sponsored by Nathan Brashares Sackett.

RECRUITING
Registry status
Phase 2
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

This study is a phase 2 single-site, double-blind, placebo-controlled, randomized clinical trial with an open-label extension phase to examine the safety of psilocybin (25 mg) combined with psychological support (Psi-PS) for treatment of approximately 40 military veterans and first responders (ages 21-65) with co-occurring alcohol use disorder (AUD) and posttraumatic stress disorder (PTSD). Psychological support is defined as providing safety, reassurance, active listening, and empathetic presence during the drug administration session in a nondirective manner. We hypothesize that Psi-PS may provide a safe treatment for participants. The primary objective of study is to characterize the safety of psilocybin combined with psychological support (Psi-PS) for individuals with co-occurring alcohol use disorder (AUD) and PTSD.

Conditions Studied

PTSD Alcohol Use Disorder (AUD)

Interventions

  • DRUG Psilocybin 25 mg
  • DRUG Maltodextrin (Placebo)

Study Locations (1)

Washington

  • University of Washington Center for Novel Therapeutics in Addiction Psychiatry - Seattle

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2025-06-01
Est. Completion 2026-06-01
Phase Phase 2

Sponsor

Nathan Brashares Sackett

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06853912

The ClinicalTrials.gov registry entry for NCT06853912 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 302-participant average among 154 other PTSD trials with a reported enrollment target (87% lower). The listed sponsor is Nathan Brashares Sackett, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with PTSD appearing as the primary indexed condition, and to 2 interventions - of which Psilocybin 25 mg is the first listed.

NCT06853912 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.

Frequently Asked Questions

What is clinical trial NCT06853912 about?

NCT06853912 is a clinical study titled "Psilocybin With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring PTSD & Alcohol Use Disorder (AUD)". This study is a phase 2 single-site, double-blind, placebo-controlled, randomized clinical trial with an open-label extension phase to examine the safety of psilocybin (25 mg) combined with psychological support (Psi-PS) for treatment of approximately 40 military veterans and first responders (ages ...

What is the current status of trial NCT06853912?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-06-01. Estimated completion is 2026-06-01.

What conditions does trial NCT06853912 study?

This clinical trial studies the following conditions: PTSD, Alcohol Use Disorder (AUD).

What interventions are being tested in trial NCT06853912?

The interventions under investigation include: Psilocybin 25 mg (DRUG), Maltodextrin (Placebo) (DRUG).

Who is sponsoring clinical trial NCT06853912?

This trial is sponsored by Nathan Brashares Sackett, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06853912 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for PTSD

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

PTSD

All registered trials for this condition

Alcohol Use Disorder (AUD)

All registered trials for this condition

Washington

All trials with a study site in Washington

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.